BrightGene Bio-Medical Technology Co., Ltd. is a research-driven biopharmaceutical company dedicated to the research, development, and manufacturing of innovative medicines, as well as special generic APIs and FDFs, with a primary strategic focus on the regulated market. The company boasts a promising innovative pipeline that includes immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumours, and novel non-antibody dependent tumour-targeting conjugates for brain cancer and solid tumour brain metastasis.

Services include:
– APIs (Active Pharmaceutical Ingredients)
– Biologics
– Innovative medicines
– Special generic APIs
– Finished dosage forms (FDFs)
– Immuno-oncological therapeutic agents
– GLP-1RA peptides
– Antibody drug conjugates

BrightGene Bio-Medical Technology Co., Ltd. continues to make significant strides in the biopharmaceutical industry, leveraging its innovative pipeline to enhance patient outcomes. For more information, please visit bright-gene.com.